(Q33213041)

24 July 2017

1 reference

title

Alteplase and ischaemic stroke: have new reviews of old data helped? (English)

1 reference

24 July 2017

2

Joanna M Wardlaw

1 reference

24 July 2017

Richard I Lindley

1

1 reference

24 July 2017

Peter A G Sandercock

series ordinal

3

1 reference

24 July 2017

publication date

1 April 2005

1 reference

24 July 2017

1 reference

24 July 2017

volume

4

1 reference

24 July 2017

issue

4

1 reference

24 July 2017

page(s)

249-253

1 reference

Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Community use of intravenous tissue plasminogen activator for acute stroke: results of the brain matters stroke management survey.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Thrombolysis for acute ischaemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Truths about the NINDS study: setting the record straight

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Should physicians give tPA to patients with acute ischemic stroke? Against: and just what is the emperor of stroke wearing?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Hea

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Underfunding of stroke research: a Europe-wide problem.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Adding to the effectiveness of intravenous tissue plasminogen activator for treating acute stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2805%2970044-2

7 January 2021

10.1016/S1474-4422(05)70044-2

Identifiers

DOI

1 reference

24 July 2017

1 reference